Latest Distribution Strategy News

ARENA REIT has announced its latest quarterly dividend of AUD 0.045625 per security, accompanied by a Dividend Reinvestment Plan offering a 1.5% discount to shareholders.

Universal Biosensors reports a 6% sales increase in Q1 2025, driven by strong growth in wine and veterinary biosensors, while preparing to launch its innovative water testing product later this year.

GPT Group has confirmed a fully unfranked ordinary dividend of AUD 0.12 per security for the six months ending December 2024, payable on February 28, 2025.

BKI Investment Company Limited has updated its dividend announcement, confirming a fully franked ordinary dividend of AUD 0.039 per share and providing key details on its Dividend Reinvestment Plan (DRP).

MyEco Group Ltd is advancing its transformation into a global leader in sustainable packaging, refining its sales and production strategies to drive growth and achieve positive EBITDA.

Garda Property Group reported a net loss of $10.19 million for the half-year ended December 31, 2024, yet maintained its interim dividend, signaling resilience amid asset value declines.

Australian Foundation Investment Company Limited has extended its on-market buy-back facility for another year, updating broker details and increasing the maximum shares to be repurchased as part of ongoing capital management.

Tissue Repair Limited reports initial patient enrolment in its pivotal Phase 3 trial for TR987®, alongside a robust 35% quarterly sales increase for its TR Pro+® product. The company is also advancing manufacturing and distribution strategies to support growth.

Terragen Holdings reports robust quarterly progress, highlighted by successful beef feedlot trials and a $4.76 million equity raise, setting the stage for its new probiotic product launch in March 2025.

Clime Investment Management has reported a return to profitability in the December half, proposing an interim dividend and unveiling strategic initiatives to drive future growth.

Biome Australia Limited has expanded its distribution footprint to over 6,000 health retail and practitioner locations, marking a 20% increase in six months and advancing toward its Vision 27 target of 8,000 sites by FY27.

EZZ Life Science Holdings delivered a robust Q2 FY25 with a 16.6% increase in customer receipts and a 308% jump in operating cash flows, while gearing up for US market entry and expanding its global footprint.